Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.56 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.47 |
| ▸ | GPR6 | P46095 | 6/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.46 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL223791 | 0.94 | GPR119 (0.64) | GPR119PDE4BGPR6ALK | |
| SCHEMBL21824767 | 0.85 | USP30 (0.50) | USP30GPR6 | |
| SCHEMBL28719769 | 0.84 | GPR119 (0.58) | GPR119PDE4BUSP30PIK3CDPIK3CA | |
| SCHEMBL30140331 | 0.84 | GPR119 (0.58) | GPR119PDE4BUSP30PIK3CDPIK3CA | |
| SCHEMBL20439351 | 0.84 | GPR119 (0.58) | GPR119PDE4BUSP30PIK3CDPIK3CA | |
| SCHEMBL29363719 | 0.84 | GPR119 (0.58) | GPR119PDE4BUSP30PIK3CDPIK3CA | |
| SCHEMBL20439353 | 0.84 | GPR119 (0.58) | GPR119PDE4BUSP30PIK3CDPIK3CA | |
| SCHEMBL13419720 | 0.84 | GPR119 (0.58) | GPR119PDE4BUSP30PIK3CDPIK3CA | |
| SCHEMBL27150331 | 0.82 | GPR119 (0.47) | GPR119USP30GPR6ALK | |
| SCHEMBL24117836 | 0.82 | GPR119 (0.79) | GPR119USP30PIK3CDALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210392895-A1 | NOVEL OXADIAZOLES | PI INDUSTRIES LIMITED (IN) | 2021-12-23 | — | — | US | disclosed |
| WO-2020070610-A1 | NOVEL OXADIAZOLES | PI INDUSTRIES LTD. (IN) | 2020-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210392895-A1 | NOVEL OXADIAZOLES | OXA1L, CYP1B1, CYP1A1 | GPR119 741/4885PDE4B 503/4885USP30 4128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.